Home›Research›Compare›GLP-1 (7-37) vs Semaglutide
Peptide ComparisonGLP-1 (7-37) vs Semaglutide
Both are Metabolic peptides.
GLP-1 (7-37)
GLP-1 fragment
33 providers listed
Semaglutide
GLP-1
Half-life: ~7 days (once-weekly dosing)
806 providers listed
Semaglutide is FDA-approved, while GLP-1 (7-37) is not evaluated — the clearest structural difference between them.
GLP-1 (7-37)
Half-life
—
Semaglutide
Half-life
~7 days (once-weekly dosing)
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | Semaglutide |
| Further along in FDA review | Semaglutide |
| Oral administration option | Semaglutide |
| More provider options (33 vs 806) | Semaglutide |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
GLP-1 (7-37)
Semaglutide
Semaglutide
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Obstetrical and medical outcomes following GLP-1 receptor agonist exposure in pregnancy: a case series.
+1 more
About GLP-1 (7-37)
Binds GLP-1 receptors in the pancreas, gut, and brain. Stimulates glucose-dependent insulin secretion and suppresses glucagon. Central GLP-1 receptor activation reduces food intake via hypothalamic pathways.
About Semaglutide
Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone GLP-1, stimulating glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying. Central GLP-1 receptor activation in the hypothalamus and brainstem reduces appetite and caloric intake. Its extended half-life of approximately seven days is achieved via structural modifications including a C18 fatty diacid chain enabling reversible albumin binding.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
GLP-1 (7-37)
Class-based (investigational)
Semaglutide
Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).
Source: FDA label
FDA prescribing protocols track HbA1c and fasting glucose for glycemic response, calcitonin for thyroid C-cell risk (black box warning), and lipase for pancreatitis screening. Baseline renal and hepatic panels are standard.
GLP-1 (7-37)
Not enough vendor pricing yet.
Semaglutide
Where to source these peptides
GLP-1 (7-37)
33 listed
Browse directory →
Providers offeringSemaglutide
806 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Metabolic Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated August 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). GLP-1 (7-37) vs Semaglutide — Per-mg Price Comparison. Retrieved September 12, 2026, from https://peptidebase.io/peptides/compare/glp-1-7-37/semaglutide